EZH2 and cancer: In recent developments in cancer therapy, specific inhibitors, such as tazemetostat, which targets enhancer of zeste homolog 2 (EZH2) and thereby mediates histone H3 lysine (K) 27 methylation, have been approved by the Food and Drug Administration (FDA) for the treatment of follicular lymphoma and are currently in use.